ISSN: 2329-6917
Journal of Leukemia
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
Case Report
Open Access

CD30+ Cells in Lung of Indolent Type Adult T-Cell Leukemia/Lymphoma and Elevated Serum Levels of Soluble CD30 Associated with Acute Crisis and Relapse of Disease

Shigeki Takemoto1,2*, Yoshitaka Morimatsu3, Ratiorn Pornkuna1,4, Toshihiko Murayama4,5 and Fumio Kawano2
1Department of International Medical Cooperation, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
3Department of Environmental Medicine, Kurume University School of Medicine, Fukuoka, Japan
4Institute for Clinical Research, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
5Department of Pathology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
Corresponding Author : Shigeki Takemoto, MD, PhD
Clinical Laboratory, National Hospital Organization Kumamoto Medical Center 1-5 Ninomaru
Chuo-ku, Kumamoto 860-0008, Japan
Tel: +81-(0)96-353-6501
Fax: +81-(0)96-325-2519
Received October 8, 2014; Accepted November 18, 2014; Published November 20, 2014
Citation: Takemoto S, Morimatsu Y, Pornkuna R, Murayama T, Kawano F (2014) CD30+ Cells in Lung of Indolent Type Adult T-Cell Leukemia/ Lymphoma and Elevated Serum Levels of Soluble CD30 Associated with Acute Crisis and Relapse of Disease. J Leuk (Los Angel) 2:166. doi:10.4172/2329-6917.1000166
Copyright: © 2014 Takemoto S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Visit for more related articles at Journal of Leukemia


Changes in the serum level of the soluble form of CD30 (sCD30) in a patient with adult T-cell leukemia/lymphoma were monitored throughout the indolent phase, acute crisis, and relapse. The level of sCD30 was elevated prior to the development of laboratory data abnormalities. In addition, the elevated sCD30 level was associated with clinical manifestations in the lung, including malignant pleural effusion, which is a diagnostic criterion of acute crisis. The sCD30 level correlated with clinical aggressiveness, and the lung lesion reoccurred on the same side as the original lesion. These data suggest that microenvironment or minimal residual disease formed in the right lung. Pathological examination of lung biopsy at the indolent phase revealed accumulated CD30+ cells among CD3+CD45RO+ T cells. The serum level of sCD30 correlated with clinical aggressiveness, indicating that the small population of CD30+ cells plays an important role in the progression of adult T-cell leukemia/lymphoma.

CD30; Adult T-cell leukemia/lymphoma (ATLL); Human T-leukemic virus type 1 (HTLV-1); Indolent type; Acute crisis
ATLL: Adult T-Cell Leukemia/Lymphoma; CCR4: C-C Chemokine Receptor Type 4; CR: Complete Remission; HTLV-1: Human TLeukemic Virus Type 1; LDH: Lactate Dehydrogenase; Scd30: Serum Soluble form of CD30; Sil-2R: Soluble Interleukin-2 Receptor Alpha Chain
Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive leukemia/lymphoma that was first proposed as a new disease entity in 1977 [1,2]. More than 1,000 patients die of ATLL every year in Japan. More than 50% of Japanese ATLL patients are from Kyushu in the southwestern part of Japan. ATLL has a broad clinical spectrum and is classified into different subtypes (acute, chronic, smoldering, and lymphoma-type ATLL) according to clinical and laboratory criteria [3,4]. Previous studies reported 4-years survival rates with the median survival time for chronic and smoldering type were 26.9% (24.3 months) and 62.8% (not yet reached), while those for acute and lymphoma-type were 5.0% (6.2 months) and 5.7% (10.2 months), respectively [5]. This is the reason why chronic and smoldering types of ATLL are considered indolent and are managed without conventional chemotherapy until disease progresses to acute crisis [6]. Approximately 70% of cases of indolent-type ATLL progressed to acute ATLL with a median duration of follow-up of 4.1 years, and 65.1% of these patients died of acute ATLL after crisis [6]. It was demonstrated that soldering/chronic ATLL peripheral blood mononuclear cells (PBMC) spontaneously proliferated ex vivo in a cytokine–dependent manner, while acute type ATLL PBMC proliferated independent of cytokines [7]. Such a transition of HTLV-1-infected cells from cytokine–dependent to cytokine– independent growth requires a constitutive activation of STAT proteins [8]. Therefore, indolent-type ATLL are thought to be as the early stage of ATLL development. Lung lesions and cutaneous lesions are involved in the early stage of ATLL.
CD30 is a member of the tumor necrosis factor receptor superfamily and induces proliferation or apoptosis depending on the cell type [9]. Activation of CD30 via its ligand, CD153, or antibodies triggers the activation of cells and the shedding of CD30. We previously investigated the clinical significance of membrane-bound CD30 expression and the serum soluble form of CD30 (sCD30) levels and determined the relationship between sCD30 levels and other serum markers in ATLL [7].
To explore the correlation between the progression of ATLL and the serum level of soluble cytokine receptors, we studied one patient throughout the indolent phase, acute crisis, and relapse of ATLL.
Case Report
A-58-year-old man was referred to the National Hospital Organization (NHO) Kumamoto Medical Center in August 2006 due to cutaneous lesions, abnormal chest x-ray, and abnormal peripheral blood test results. He had experienced pulmonary tuberculosis 10 years earlier. A positive antibody for human T-leukemia virus type 1 (HTLV-1) was identified. Physical examination of the patient revealed cutaneous lesions that appeared similar to mycosis fungoides. A biopsy of a skin lesion was performed, and the diagnosis was T-cell lymphoma compatible with ATLL. Bronchial endoscopy was performed, because diffuse bronchiolitis was suspected. A diagnosis of HTLV-1-associated bronchoalveolar disorder was considered. However, the findings from a transbronchial lung biopsy were not remarkable. The patient was admitted to the hospital for further examination via video-assisted thoracic surgery. The pathological findings showed lymphoma cell infiltration, compatible with T-cell lymphoma (Figures 1A and 1B). Therefore, this patient was diagnosed with HTLV-1-associated bronchopneumopathy and smoldering-type ATLL. Antibiotics were administered for methicillin-resistant Staphylococcus aureus , and itraconazole was administered for Candida albicans . The cutaneous lesions disappeared without antitumor therapy.
ATLL is diagnosed according to Shimoyama’s criteria, and there are four subtypes of ATLL [5]. Acute crisis was later proposed as an additional condition in the clinical course of ATLL. There are no established criteria for acute crisis, but the critical features from a comparison between acute-type and chronic-type ATLL are summarized in Table 1. In acute-type ATLL, the lactate dehydrogenase (LDH) level is higher than twice the upper limit of normal. Acute-type ATLL is also characterized by hypercalcemia, which can cause death; hypercalcemia can be diagnosed by clinical symptoms and a blood test. Finally, central nervous system tumors, malignant ascites, malignant pleural effusion, and gastrointestinal tract tumors are very specialized to acute-type ATLL.
In May 2007, the patient developed pulmonary complications associated with pleural effusion (Figure 2A). Treatment with antibiotics had no effect. Clinical laboratory data indicated progression of anemia, hypoalbuminemia, and ATLL. Serum levels of LDH, sIL-2R, and sCD30 were elevated as compared with data of indolent phase (142 days before crisis) (Table 2). Only the appearance of pleural effusion indicated the acute crisis in addition to the pulmonary invasion of ATLL cells and lymphadenopathy as a feature of indolent type ATLL (Figures 2A and 2B). We started three cycles of multi-agent chemotherapy (mLSG15) for aggressive ATLL, which was based on the Japan Clinical Oncology Group protocol (Figure 3A) [10]. This therapy led to a complete remission (CR). The soluble CD30 level was elevated prior to acute crisis and normalized during the CR state (Figure 3). The patient elected to receive chemotherapy but not allogeneic hematopoietic stem cell transplantation because of his desire to continue his employment without prolonged interruption. Although the patient’s condition remained stable for more than 1 year during supportive therapy, cutaneous lesions subsequently appeared, and the patient relapsed (Figure 3B). He then underwent mogamulizumab treatment, a new monoclonal antibody therapy against C-C chemokine receptor type 4 (CCR4) on the surface of ATLL cells (KW-0761) [11]. However, the level of soluble CD30 increased, and the right lung lesion reoccurred; therefore, the mLSG-15 regimen was started again following four cycles of KW-0761. The development of pancytopenia and immunodeficiency resulted in the discontinuation of chemotherapy. Cytomegalovirus antigenemia testing indicated reactivation of this virus.
To investigate the sCD30-producing cells, immune staining was performed with an antibody panel including CD30 (Ki-1), CD3, CD45RO (UCHL-1), and CD20 (B26). Pathophysiological study demonstrated that accumulated CD30+ cells were shown among the T cells but not among B cells (Figure 4).
In this case report, we described the clinical course of a patient who progressed from indolent-type to acute-type ATLL with lung invasion following elevation of the serum sIL-2R and sCD30 levels. The serum levels of both soluble proteins remained high and were elevated prior to the acute crisis of ATLL. Furthermore, the level of sCD30 increased according to the formation of pulmonary lesions at relapse as well as during the acute crisis of disease. The sCD30-producing cells corresponded to accumulated CD30+ T cells in the lung.
The lungs are the preferential site for HTLV-1–infected cells, and this peculiar tropism is responsible for the high incidence of pulmonary involvement [12-14]. In our case, massive lymphadenopathy in the mediastinum and pleural effusion was observed, and infections were excluded as a cause, because these findings improved in response to mLSG15 therapy. The same right lung was involved at relapse, suggesting that there was microenvironment or minimum residual disease in the right lung. In the lung, Tax, a trans-activator of the HTLV-1 genome and cellular genes, is preferentially expressed in HTLV-1-infected cells [14,15], and the CD30 and CD30 ligand interaction plays an important role in inflammation [16,17]. Therefore, a sustained high level of sCD30 may be associated with Tax expression and pulmonary involvement of ATLL.
The main limitation of the present study is that only one patient was studied. Although HTLV-1 is endemic in Kyushu, the incidence of ATLL is very low, and a long latency period exists between HTLV-1 infection and the development of ATLL. A multicenter cohort study is needed to confirm our results.
In conclusion, we demonstrated that the level of sCD30 was elevated during the process of acute crisis and of ATLL. Chronic immune activation in the lung and in pulmonary lesions may be a major cause for the sustained proliferation of ATLL cells and the progression of ATLL. Therefore, prospective monitoring using sCD30 may be effective to confirm the progression of disease.
We thank Prof. Yoshio Haga for supporting this clinical research, and we thank the members of the Department of Hematology of NHO Kumamoto Medical Center for their collaboration on the present report. This study was supported in part by research funding from Kyowa Medex Co., Ltd. (Tokyo, Japan) and Kyowa Hakko Kirin (Tokyo, Japan) to ST.


Tables at a glance

image   image
Table 1   Table 2


Figures at a glance

image   image   image   image
Figure 1   Figure 2   Figure 3   Figure 4
Select your language of interest to view the total content in your interested language
Share This Article
Relevant Topics
Disc Acute Lymphoblastic Leukemia
Disc Acute Megakaryocytic Leukemia
Disc Acute Myelomonocytic Leukemia
Disc Acute Myleoid Leukemia
Disc Advances in Alternative Lung Cancer Treatment
Disc Aleukemic Leukemia
Disc Anaemia Symptoms
Disc Anemia Causes
Disc Anti-Cancer Drug
Disc Antiphospholide Antibody Syndrome
Disc Autoimmune Disorder
Disc Autoimmune Haemolytic Anaemia
Disc Blood
Disc Blood Cancer
Disc Blood Cancer Symptoms
Disc Blood Clot in Brain
Disc Blood Clots
Disc Blood Group
Disc Blood Lymphocytes
Disc Bone Cancer Stages
Disc Bone Marrow Cancer Survival
Disc Brain Tumor Treatment
Disc Cancer Science
Disc Cancer Therapies
Disc Cancer therapy
Disc Cellular Oncology
Disc Chemo Resistance
Disc Chronic Lymphocytic Leukemia
Disc Chronic Myleloid Leukemia
Disc Clinical Oncology
Disc Comparative Oncology
Disc Dental Oncology
Disc Electro Chemotherapy
Disc Eosinophilia
Disc Esophageal Cancer
Disc Factor XIII
Disc Feline Leukemia Complex
Disc Genitourinary Oncology
Disc Gynecological Cancers
Disc Haematologist
Disc Haemolytic Anaemia
Disc Haemolytic Disease of the Newborn
Disc Haemophilia
Disc Haemostasis
Disc Hairy Cell Leukemia
Disc Interventional Oncology
Disc Iron Test
Disc Juvenile Myelomonocytic Leukaemia
Disc Kidney Cancer Prognosis
Disc Large Cell Lymphoma
Disc Leukemia
Disc Leukemia Drugs
Disc Leukemia Symptoms
Disc Leukopenia
Disc Lung Tumor
Disc Lungs Cancer Cure
Disc Lupus
Disc Lymph Node Cancer
Disc Lymphocytosis
Disc Lymphoma Cancer
Disc Lymphoma Symptoms
Disc Lymphosarcoma
Disc Mast Cell Leukemia
Disc Molecular Oncology
Disc Morbus Hodgkin
Disc Multiple Myeloma
Disc Musculoskeletal Oncology
Disc Myeloma
Disc Neutropenia
Disc Neutrophilic Leukocytosis
Disc Oncology Analytics
Disc Oncology Emergency
Disc Oncology Esthetics
Disc Oncology Nutrition
Disc Oseophagus Cancer
Disc Ovarian Cancer and Prognosis
Disc Pancreatic Cancer
Disc Pediatric Leukemia
Disc Plasma Cell Disorder
Disc Plasma Cell Leukemia
Disc Radio Oncology
Disc Radiotherapy
Disc Red Blood Cells
Disc Sarcoma Cancer
Disc Sickle Cell Disease
Disc Sickle Cell Trait
Disc Spleen Cancer
Disc Squamous Cell Carcinoma
Disc Systematic Lupus Erythematous
Disc T-cell Lymphomas
Disc Thoracic Oncology
Disc Tumorigenesis
Disc Veterinary Oncology
Disc White Blood Cell
Recommended Journals
Disc Blood Disorders Journal
Disc Integrative Oncology Journal
Disc Blood Journal
Disc Chemotherapy Journal
Disc Cancer Science Journal
  View More»
Recommended Conferences
Disc 5th Hemophilia Congress
June 06-08 London, UK
Disc Molecular and Cancer Biomarkers Conference
Jul 28-29, 2016 Berlin, Germany
Disc 3rd World Congress on Women’s Health and Breast Cancer
October 03-05, 2016 London, UK
Disc Leukemia and Bone Marrow Transplantation Conference
Nov 10-12, 2016, Istanbul, Turkey
Disc 6th Hematology and Lymph Conference
Nov 14-16, 2016 San Francisco, USA
Article Tools
Disc Export citation
Disc Share/Blog this article
Article usage
  Total views: 11231
  [From(publication date):
December-2014 - May 26, 2016]
  Breakdown by view type
  HTML page views : 7503
  PDF downloads :3728

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
OMICS International Conferences 2016-17
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version